PARRY, ROMANI, DECONCINI & SYMMS for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Financial Institutions/Investments/Securities FIN
Monitor legislation reforming the Committee on Foreign Investment in the United States process.
Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD H BAXTER | — |
| DENNIS DECONCINI | — |
| JAMES ROCK | — |
| ROMANO ROMANI | — |
| THADDEUS E STROM | — |
| STEVE SYMMS | — |
Copyright/Patent/Trademark CPT
Oppose importation of unsafe drugs from outside the United States. Monitor S. 1145 and H.R. 1082, Patent Law Reform. Support amendments to strengthen patent enforcement.
Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD H BAXTER | — |
| DENNIS DECONCINI | — |
| JAMES ROCK | — |
| ROMANO ROMANI | — |
| THADDEUS E STROM | — |
| STEVE SYMMS | — |
Medical/Disease Research/Clinical Labs MED
Support efforts to obtain approval of at least one more compendia by the Department of Health and Human Services for use in Medicare reimbursement decisions for cancer medications. S. 1505 - Affordable Biologics for Consumers Act S. 1695 Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity. H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007
Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD H BAXTER | — |
| DENNIS DECONCINI | — |
| JAMES ROCK | — |
| ROMANO ROMANI | — |
| THADDEUS E STROM | — |
| STEVE SYMMS | — |
Law Enforcement/Crime/Criminal Justice LAW
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD H BAXTER | — |
| DENNIS DECONCINI | — |
| JAMES ROCK | — |
| ROMANO ROMANI | — |
| THADDEUS E STROM | — |
| STEVE SYMMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.